Clinical trial
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
NCT00045968 is registered in ClinicalTrials.gov with Northwest Biotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
- Lead sponsor
- Northwest Biotherapeutics
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 31, 2006
- Completion date
- Not reported
- Enrollment
- 348 (estimated)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.
brain cancer, brain tumor, gbm, glioblastoma, glioblastoma multiforme, glioma, grade iv astrocytoma